newsfilter
← Latest News
Business Wire·

Zura Bio Announces Proposed Public Offering of Class A Ordinary Shares and Pre-Funded Warrants

ZURA
  • Zura Bio Limited (NASDAQ: ZURA) has commenced an underwritten public offering of Class A ordinary shares & pre-funded warrants to purchase Class A ordinary shares.
  • The company expects to grant underwriters a 30-day option to purchase additional shares up to 15% of the aggregate shares & warrants sold in the offering.
  • Leerink Partners, Piper Sandler, & Cantor are acting as joint bookrunning managers, while Wedbush PacGrow serves as the lead manager.
  • The offering is being made pursuant to a shelf registration statement on Form S-3 filed with the SEC on September 3, 2024, & declared effective on September 17, 2024.
  • All Class A ordinary shares & pre-funded warrants in the proposed offering will be sold by Zura.
  • Zura is a clinical-stage biotechnology company developing dual-pathway antibodies for autoimmune & inflammatory diseases.
  • Lead candidate tibulizumab (ZB-106) is being evaluated in Phase 2 studies for hidradenitis suppurativa (TibuSHIELD) & systemic sclerosis (TibuSURE).
  • Product candidates crebankitug (ZB-168) & torudokimab (ZB-880) have completed Phase 1/1b studies & are being evaluated for potential use in various autoimmune & inflammatory conditions.
  • The completion, actual size, & terms of the proposed offering are subject to market conditions & other risks.